NOVADUR Trademark

Trademark Overview

On Monday, September 26, 2016, a trademark application was filed for NOVADUR with the United States Patent and Trademark Office. The USPTO has given the NOVADUR trademark a serial number of 87183143. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Tuesday, March 10, 2020. This trademark is owned by Allergan, Inc.. The NOVADUR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, a drug delivery system comprising a solid biodegradable polymer based sustained drug release formulation for use with an applicator for intraocular injections
novadur

General Information

Serial Number87183143
Word MarkNOVADUR
Filing DateMonday, September 26, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateTuesday, March 10, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 10, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, a drug delivery system comprising a solid biodegradable polymer based sustained drug release formulation for use with an applicator for intraocular injections

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 29, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAllergan, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612
Party NameAllergan, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Trademark Events

Event DateEvent Description
Friday, May 8, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Friday, May 8, 2020ABANDONMENT - NO USE STATEMENT FILED
Wednesday, September 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 10, 2019EXTENSION 5 GRANTED
Friday, September 6, 2019EXTENSION 5 FILED
Tuesday, September 10, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, September 6, 2019TEAS EXTENSION RECEIVED
Friday, February 8, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 6, 2019EXTENSION 4 GRANTED
Wednesday, February 6, 2019EXTENSION 4 FILED
Wednesday, February 6, 2019TEAS EXTENSION RECEIVED
Friday, September 7, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 5, 2018EXTENSION 3 GRANTED
Wednesday, September 5, 2018EXTENSION 3 FILED
Wednesday, September 5, 2018TEAS EXTENSION RECEIVED
Wednesday, September 5, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 31, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 29, 2018EXTENSION 2 GRANTED
Monday, January 29, 2018EXTENSION 2 FILED
Monday, January 29, 2018TEAS EXTENSION RECEIVED
Wednesday, August 16, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 14, 2017EXTENSION 1 GRANTED
Monday, August 14, 2017EXTENSION 1 FILED
Monday, August 14, 2017TEAS EXTENSION RECEIVED
Wednesday, March 8, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 10, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 10, 2017PUBLISHED FOR OPPOSITION
Wednesday, December 21, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, December 5, 2016ASSIGNED TO EXAMINER
Thursday, September 29, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, September 29, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

novadur drug release sustained based formulation applicator injections intraocular polymer biodegradable